Le Lézard
Classified in: Health, Science and technology
Subject: MRR

Worldwide Lyophilization Services for Biopharmaceuticals Industry Report to 2035 - Key Market Trends and Forecasts


DUBLIN, May 16, 2022 /PRNewswire/ -- The "Lyophilization Services Market for Biopharmaceuticals by Type of Biologic Lyophilized, Type of Primary Packaging System and Key Geographies, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

This report features an extensive study of companies engaged in offering lyophilization services for biopharmaceuticals. The study features an in-depth analysis of the key drivers and trends related to this domain.

Over the last decade, a steady rise has been observed in the annual number of approvals for various types of biologics (including monoclonal antibodies, cell therapies, recombinant proteins, vaccines and gene therapies). In addition, more than 8,000 biological therapeutics are currently being evaluated in clinical trials, being conducted across the globe. Evidently, biologics have emerged as one of the fastest growing segments in the pharmaceutical industry.

Driven by several advantages offered by biologics over small molecules (including high efficacy, target specificity and favorable safety profiles), the biopharmaceutical market is anticipated to witness continued and consistent growth over the next several years. However, there are a variety of challenges associated with such therapies.

For instance, biological drugs are inherently less stable as compared to small molecules and, therefore, more prone to physical and chemical degradation. In order to achieve longer and commercially viable shelf lives, players are actively adopting the lyophilization (also known as freeze-drying) technique; it enables the production of stable dry biopharmaceutical formulations. In this context, it is worth highlighting that around 50% of the currently approved biopharmaceuticals are injectables. Of these, about one third of the drug candidates are being lyophilized.

Setting up in-house lyophilization capabilities and operations is an expensive and time-consuming process, which requires specialized lyophilization equipment and expertise. Considering the high capital investment and technical / routine operations-related challenges associated with lyophilization of biopharmaceuticals, a growing number of biologic developers are outsourcing their lyophilization operations to qualified contract manufacturing organizations (CMOs) in order to leverage their capabilities and yield cost savings opportunities.

Presently, more than 105 contract manufacturers claim to have the required capabilities to offer lyophilization services for biotherapeutics. In addition, lyophilization service providers are entering into strategic alliances in order to consolidate their presence in this field and enhance existing capabilities to meet the growing demand for biologics. Driven by the increasing preference for outsourcing, continuous growth of the biological therapeutics pipeline and a steady rise in drug approvals, the lyophilization services market for biopharmaceuticals is likely to witness steady growth in the foreseen future.

Amongst other elements, the report includes:

Key Questions Answered

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Lyophilization Service Providers for Biopharmaceuticals: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Scale of Operation
4.2.5. Analysis by Regulatory Certification / Accreditation
4.2.6. Analysis by Type of Biologic Lyophilized
4.2.7. Analysis by Process of Lyophilization
4.2.8. Analysis by Type of Primary Packaging System
4.2.9. Analysis by Additional Services Offered

5. BENCHMARK ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Benchmark Analysis: Peer Groups

6. COMPANY PROFILES: LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS IN NORTH AMERICA
6.1. Chapter Overview
6.2. Baxter BioPharma Solutions
6.2.1. Company Overview
6.2.2. Lyophilization Service Offerings for Biopharmaceuticals
6.2.3. Dedicated Biopharmaceutical Lyophilization Facilities
6.2.4. Recent Developments and Future Outlook
6.3. Curia
6.3.1. Company Overview
6.3.2. Lyophilization Service Offerings for Biopharmaceuticals
6.3.3. Dedicated Biopharmaceutical Lyophilization Facilities
6.3.4. Recent Developments and Future Outlook
6.4. Emergent BioSolutions
6.4.1. Company Overview
6.4.2. Lyophilization Service Offerings for Biopharmaceuticals
6.4.3. Dedicated Biopharmaceutical Lyophilization Facilities
6.4.4. Recent Developments and Future Outlook
6.5. LSNE Contract Manufacturing
6.5.1. Company Overview
6.5.2. Lyophilization Service Offerings for Biopharmaceuticals
6.5.3. Dedicated Biopharmaceutical Lyophilization Facilities
6.5.4. Recent Developments and Future Outlook
6.6. Lyophilization Technology
6.6.1. Company Overview
6.6.2. Lyophilization Service Offerings for Biopharmaceuticals
6.6.3. Dedicated Biopharmaceutical Lyophilization Facilities
6.6.4. Recent Developments and Future Outlook

7. COMPANY PROFILES: LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS IN EUROPE
7.1. Chapter Overview
7.2. CordenPharma
7.2.1. Company Overview
7.2.2. Lyophilization Service Offerings for Biopharmaceuticals
7.2.3. Dedicated Biopharmaceutical Lyophilization Facilities
7.2.4. Recent Developments and Future Outlook
7.3. Coriolis Pharma
7.3.1. Company Overview
7.3.2. Lyophilization Service Offerings for Biopharmaceuticals
7.3.3. Dedicated Biopharmaceutical Lyophilization Facilities
7.3.4. Recent Developments and Future Outlook
7.4. Northway Biotech
7.4.1. Company Overview
7.4.2. Lyophilization Service Offerings for Biopharmaceuticals
7.4.3. Dedicated Biopharmaceutical Lyophilization Facilities
7.4.4. Recent Developments and Future Outlook
7.5. ProJect Pharmaceutics
7.5.1. Company Overview
7.5.2. Lyophilization Service Offerings for Biopharmaceuticals
7.5.3. Dedicated Biopharmaceutical Lyophilization Facilities
7.5.4. Recent Developments and Future Outlook
7.6. Vetter Pharma
7.6.1. Company Overview
7.6.2. Lyophilization Service Offerings for Biopharmaceuticals
7.6.3. Dedicated Biopharmaceutical Lyophilization Facilities
7.6.4. Recent Developments and Future Outlook

8. COMPANY PROFILES: LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS IN ASIA PACIFIC
8.1. Chapter Overview
8.2. BioZed Engineering
8.2.1. Company Overview
8.2.2. Lyophilization Service Offerings for Biopharmaceuticals
8.2.3. Dedicated Biopharmaceutical Lyophilization Facilities
8.2.4. Recent Developments and Future Outlook
8.3. CinnaGen
8.3.1. Company Overview
8.3.2. Lyophilization Service Offerings for Biopharmaceuticals
8.3.3. Dedicated Biopharmaceutical Lyophilization Facilities
8.3.4. Recent Developments and Future Outlook
8.4. MabPlex
8.4.1. Company Overview
8.4.2. Lyophilization Service Offerings for Biopharmaceuticals
8.4.3. Dedicated Biopharmaceutical Lyophilization Facilities
8.4.4. Recent Developments and Future Outlook
8.5. Samsung Biologics
8.5.1. Company Overview
8.5.2. Lyophilization Service Offerings for Biopharmaceuticals
8.5.3. Dedicated Biopharmaceutical Lyophilization Facilities
8.5.4. Recent Developments and Future Outlook
8.6. WuXi Biologics
8.6.1. Company Overview
8.6.2. Lyophilization Service Offerings for Biopharmaceuticals
8.6.3. Dedicated Biopharmaceutical Lyophilization Facilities
8.6.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Lyophilization Services for Biopharmaceuticals: List of Partnerships and Collaborations

10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Lyophilization Services Market for Biopharmaceuticals: List of Recent Expansions

11. SURVEY ANALYSIS
11.1. Chapter Overview
11.2. Lyophilization Services Market for Biopharmaceuticals: List of Participating Companies

12. CASE STUDY I: LYOPHILIZATION CYCLE DEVELOPMENT AND OPTIMIZATION
12.1. Chapter Overview
12.2. Lyophilization Cycle Development
12.3. Lyophilization Cycle Optimization
12.4. Lyophilization Cycle Development and Optimization: List of Service Providers

13. CASE STUDY II: ALTERNATIVE APPROACHES TO LYOPHILIZATION
13.1. Chapter Overview
13.2. Alternative Approaches to Lyophilization

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Global Lyophilization Services Market for Biopharmaceuticals, 2022-2035
14.4. Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Biologic Lyophilized, 2022 and 2035
14.5. Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Primary Packaging System, 2022 and 2035
14.6. Lyophilization Services Market for Biopharmaceuticals: Distribution by Geography, 2022 and 2035

15. CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

For more information about this report visit https://www.researchandmarkets.com/r/bvt9f7

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 18:50
Getting specialty medications into...

at 18:30
Arthrex, a global leader in minimally invasive surgical technology, has once again taken home prestigious medals for product innovation at the 37th annual Edison Awards. "This product, along with our other innovations,...

at 18:23
Aligned with the trend of immersive water therapy in 2024, Baros Maldives' Serenity Spa stands out as an oasis of indulgent spa and beauty rituals, boasting a 50-year legacy of luxury. Nestled within a tranquil sanctuary amidst the lush Maldivian...

at 17:55
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...

at 17:20
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...



News published on and distributed by: